John Yu

Alice Lin-Tsing Yu

Jung-Tung Hung

Tan-Chi Fan










陳鈴津 Alice Lin-Tsing Yu, MD, PhD.
Distinguished Chair Professor, & Co- Director, Institute of Stem Cell and Translational Cancer Research
Chang Gung Memorial Hospital & Chang Gung University
Distinguished Visiting Fellow, Genomics Research Center, Academic Sinica

Office Address:

Institute of Stem Cell and Translational Cancer Research, Research building 6F, Chang Gung Memorial Hospital at Linkou, No.15, Wenhua 1st St., Kuei Shang, Taoyuan 333, Taiwan

Tel: (886-3)328-1200 ext. 7803 Fax: (886-3)328-1200 ext. 5214
123 Current Status:
  • Co-Director, Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital at Linkou
  • Distinguished Chair Professor, Chang Gung Memorial Hospital and Chang Gung University
  • Academician and Distinguished Visiting Fellow of Institute of Cellular & Organismic Biology, Academia Sinica
  • Professor in Pediatrics, University of California in San Diego (UCSD), USA

  • M.D., College/Professional School, National Taiwan University
  • M.S., Graduate School, Yale University
  • Ph.D.,Microbiology/Immunology, University of Chicago
  • Fellow,Division of Pediatric Hematology/ Oncology, Harvard University; Pediatric Residency, University of Chicago, Boston University

Focus of Interest:
  • Immunology
  • Tumor biology
  • Translational medicine
  • Clinical oncology

Professional Records:
  • 2013~present, Distinguished Chair Professor and Co-Director, Institute of Stem Cell & Translational Cancer Research, Chang Gung Memorial Hospital at Linkou and Chang Kung University
  • 2013~present, Distinguished Visiting Fellow, Genomics Research Center, Academia Sinica, Taiwan
  • 2003~present, Professor in Pediatrics, University of California in San Diego (UCSD), USA
  • 2003~2013, Distinguished Research Fellow and Associate Director, Genomics Research Center, Academia Sinica
  • 2004~2013, Joint Appointment Professor, College of Medicine, National Taiwan University
  • 2001~2003, Professor and Chief, Division of Pediatric Hematology/Oncology, University of California in San Diego (UCSD), USA
  • 1977~2003, Assistant Professor to Professor of Pediatrics, UCSD, USA

Employment Records:
  • 1977-2001 Assistant Professor through Professor of Pediatrics, University of California, San Diego
  • 2001-2003 Professor and Chief, Pediatric Hematology/Oncology, University of California, San Diego
  • 2003-2013 Distinguished Research Fellow and Deputy Director, Genomics Research Center, Academia Sinica
  • 2013-Present Distinguished Chair Professor, Chang Gung Memorial Hospital & Chang Gung University & Co- Director, Center of Stem Cell and Translational Cancer Research

Honor and Awards:
  • 2016, Academician, Academia Sinica, Taiwan
  • 2016, 105年度優良教師研究獎, 長庚大學
  • 2016, Excellence in Technology Transfer Award 2016 from Federal Laboratory Consortium, USA: “Discovery to Commercialization: New Immunotherapy for Rare Childhood Cancer, Neuroblastoma”
  • 2011, The 55th Academic Award from the Ministry of Education
  • 2009, The 19th Wang Min-Ning Memorial Award for Outstanding Contribution to the Development Medical Science and Technology, National Health and Society
  • 2001, Honored at the San Diego Padres Stadium as Community Health Heroes
  • 2001, Recipient of the Year 2000 “Key to Life” Award from the Leukemia & Lymphoma Society
  • 2000, Honored at the S.D. Padres Stadium for launching a new vaccine study for children with neuroblastoma
  • 2000, Health Hero of year 2000, awarded by the Epilepsy Society
  • 2000, Doctor of the year, Honorable Mention, UCSD Medical Center
  • 1998, Recipient of Translational Research Award, Leukemia & Lymphoma Society
  • 1997, Biotech All-Stars, San Diego Padre, Qualcome Stadium

Key Government Services and scientific advisory committees in Taiwan: (2013-present):
  • 2017, 中央研究院106年度國內院士季會召集委員
  • 2017,國衛院學術倫理專案審議委員會委員
  • 2016-present,國立台灣大學基因體醫學研究中心諮詢委員會委員
  • 2016-present,國家衛生研究院兒童醫學及健康研究中心,本國兒童醫療與健康政策2030白皮書之「兒童精準醫療」召集人
  • 2016-present, 輔英科技大學老化及疾病預防研究中心顧問
  • 2015-present, 衛福部兒童醫學及健康研究中心「兒童重難症」專案小組委員
  • 2016-present, 國家衛生研究院生技與藥物研究所科技顧問委員
  • 2013-present, 財團法人國家衛生研究院董事會董事
  • 2004-present,財團法人生物技術開發中心科技顧問會議科技顧問
  • 2004-present,行政院衛生署行政院科技組顧問「生醫科技島」、「臨床試驗與研究推動小組」指導委員
  • 2004-present, 行政院奈米國家型計劃指導委員

Current Research:
  1. Generation of novel anti-cancer therapeutics using universal cancer targeting peptide platform technologies: This is a breakthrough technology to exploit the use of our “universal” cancer targeting peptides (CTPs) as “warhead” for conjugation to various “payloads”, such as bispecific antibody (BsAb), anti-cancer mAbs and small molecules, antisense oligo/siRNA、CAR-T, etc., to design a new generation of “one-for-all” cancer therapeutics. Ideally, anticancer therapeutics carrying various payloads of drugs can be like “guided missiles” using universal CTP technologies with the capacity of targeted delivery toward many different types of cancers. Using such key CTP platform technology, we will develop plans for short, mid and long-term strategies to generate novel CTP-guided cancer therapeutics and expand clinical applications and market values.
  2. GD2-targeted Cancer Immunotherapy
    Until recently, all approved cancer immunotherapeutics target proteins but not glycans. The approval of Unituxin, a chimeric anti-GD2 antibody, ch14.18 for the treatment of high-risk neuroblastoma by US FDA and European Commission in 2015 marks the first new agent targeting a glycolipid molecule, thereby widening the net of potential pharmaceutical targets. This was largely based on the pioneer work of Dr. Yu and her leadership through the entire course of ch14.18 development culminating in a randomized phase III clinical trial,led by Dr. Yu, under the auspice of Children’s Oncology Group.This trial showed a significant improvement in 2-year event-free survival and overall survival (New Engl J Med 2010) and provided the basis forits regulatory approval.This immunotherapy has since become the new standard of care for neuroblastoma. To improve the efficacy of Unituxin, Dr. Yu proposed a COG study to combine chemotherapy with Unituxin in relapsed neuroblastoma. The impressive clinical response was showcased at ASCO 2016 and published in Lancet Oncology 2017. In collaboration with Dr.Dr. Paul Sondel (Univ of Wisconsin)specific KIR/KIR-ligand genotypes [inhibitory KIR2DL2 with its ligand (HLA-C1) together with inhibitory KIR3DL1 with its ligand (HLA-Bw4)] were identified to be associated with clinical benefit for neuroblastoma patients receiving immunotherapy. We are now developing a clinical trial of combining Unituxin with chemotherapy for newly diagnosed high risk neuroblastoma. In addition, we are developing strategies to improve the efficacy of Unituxin by combining with anti-PD1, or DFMO, an inhibitor of polyamine biosynthesis.
  3. Studies of tumor associated glycans that regulate tumor growth and tumor microenvironment: Dr. Alice L. Yu’s group has recently demonstrated that the most prevalent tumor associated glycans, Globo H ceramide, acts as an immune checkpoint to aid evasion of tumor cells from immune surveillance, presumably via cell-to-cell transfer through exosomes. In addition, it displays angiogenic activities for endothelial cells, thereby promoting tumor growth. These new findings provided strong rationales for the ongoing development of Globo H targeted cancer immunotherapy. In fact, a randomized trial of Globo H vaccine in metastatic breast cancer designed by her has shown significant survival benefits for those who developed anti-Globo H responses (ASCO, 2016). Now we will focus on the molecular processes involved in theimmune suppression mediatedtumor associated glycans. Such findings will be further exploited for potential clinical applications in the treatment of autoimmune disorders, allograft transplantation, and fetus/endometrial crosstalk.
  4. Delineate roles of ST3Gal1 mediated O-sialylated proteins in breast cancer and angiogenesis: ST3Gal1 (ST3 beta-galactoside alpha-2,3-sialyltransferase 1) catalyzes the transfer of sialic acid in an 2,3 linkage to Gal 1-3-GalNAc-Ser/Thr, and thus terminate further chain elongation. It has been reported that core 1 and sialylated core 1 O-glycans on Muc1, such as Sialyl3 T and Sialyl6 T structures, were increased in breast cancers.ST3Gal1 mRNA expression is elevated in primary breast carcinoma cells compared to normal or benign breast tissues. Our data showed that ST3Gal1 silencing suppressed in vitro and in vivo growth of breast cancer cells. We are the first to identify several protein targets of ST3Gal1 and are in the process of elucidating how ST3Gal1 mediated sialylated proteins affect the behavior of breast cancers and angiogenesis.
  5. Determine the circulating glycan-specific antibodies and clinical significance of glycosyltransferase profiles and identify glycan target for therapy: Cell surface glycoproteins/glycolipids have been shown to play important roles in a wide variety of biological functions;however, glycan structures on the glycoprotein/glycolipid are altered in cancer. Many tumor-associated carbohydrate antigens have been identified, including GD2, GD3, TF, Tn, sialyl T, sialyl Lewis x, and Globo H, on cancer cells.Therefore, the glycan-conjugated lipids or proteins produced during tumorigenesis could be served as biomarkers for breast cancer. In addition, fucosylation and sialylation are the most common glycosylation found in tumor. The glycosyltransferases, which are responsible for adding fucose or sialic acid to the end of the tumor-associated carbohydrate antigens, are also down-/up-regulated during tumorigenesis.We are investigating severalpotential new biosignatures of breast cancer and its relevance to clinical outcomes, including glycan-specific autoantibodies, levels of fucosyltransferases/sialyltransferases and B3GalT5 and expression of Globo H and SSEA3 in tumor.
  6. Integration of Taiwan Pediatric Oncology Group for molecular diagnosis and treatment of childhood cancer整合台灣兒童癌症臨床治療及分子診斷:
    1. Develop new immunotherapy protocol for the treatment of high risk neuroblastoma by combining anti0GD2 with induction chemotherapy, so as to improve the treatment outcome (co-PI陳世翔醫師&Dr. Alice Yu)
    2. Integrate and standardize the molecular diagnostic tests for childhood brain tumor in accordance to international standards to deliver individually tailored therapy (co-PI黃棣棟教授, 北醫).
    3. Establish website for TPOG, providing web access for treatment protocols and roadmaps, integrating clinical data collection and analyses, and implement a plan to develop a tissue bank for childhood brain tumor and neuroblastoma specimens to facilitate future research. (co-PI黃棣棟教授, 北醫;黃秀芬醫師,國衛院; Dr. Alice Yu)
    4. Analyze the health economics of acute lymphoblastic leukemia (ALL)to examine entire costs of care for children with ALL (co-PI鄭竹珊助理教授,長庚大學;王榮德教授,成大; Dr. Alice Yu).

Publications (2013-2017 selected papers):
  1. Chan Y.T., Lin Y.C., Lin R.J., Kuo H.H., Thang W.C., Chiu K.P., Yu A.L.* Concordant and discordant regulation of target genes by miR-31 and its isoforms. PLoS One 2013, 8(3): e58169.
  2. Chang B.M., Lin H.H., Su L.J., Lin W.D., Lin R.J., Tzeng Y.K., Lee R.T., Lee Y.C., Yu A.L.*, Chang H.C.* Highly Fluorescent Nanodiamonds Protein-Functionalized for Cell Labeling and Targeting. Advanced Functional Materials 2013, 23(46): 5737-5745.
  3. Chang W.W., Lin R.J., Yu J., Chang W.Y., Fu C.H., Lai A.C., Yu J.C., Yu A.L.* The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors. Breast Cancer Res 2013, 15(3): R39.
  4. Chen Y.J., Thang M.W., Chan Y.T., Huang Y.F., Ma N., Yu A.L., Wu C.Y., Hu M.L., Chiu K.P.* Global assessment of Antrodia cinnamomea-induced microRNA alterations in hepatocarcinoma cells. PLoS One 2013, 8(12): e82751.
  5. Huang Y.L., Hung J.T., Cheung S.K., Lee H.Y., Chu K.C., Li S.T., Lin Y.C., Ren C.T., Cheng T.J., Hsu T.L., Yu A.L.*, Wu C.Y.*, Wong C.H.* Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer. Proc Natl Acad Sci U S A 2013, 110(7): 2517-2522.
  6. Kreissman S.G., Seeger R.C., Matthay K.K., London W.B., Sposto R., Grupp S.A., Haas-Kogan D.A., Laquaglia M.P., Yu A.L., Diller L., Buxton A., Park J.R., Cohn S.L., Maris J.M., Reynolds C.P., Villablanca J.G. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol 2013, 14(10): 999-1008.
  7. Sawant R.C., Hung J.T., Chuang H.L., Lin W.S., Chen W.S., Yu A.L.*, Luo S.Y.* Synthesis of Hydroxylated Analogues of a-Galactosyl Ceramide (KRN7000) with varying stereochemistry. Eur J Org Chem 2013, 2013(33): 7611-7623.
  8. Tsai Y.C., Huang J.R., Cheng J.Y., Lin J.J., Hung J.T., Wu Y.Y., Yeh K.T., Yu A.L.* A Prevalent Cancer Associated Glycan, Globo H Ceramide, Induces Immunosuppression by Reducing Notch1 Signaling. Journal of Cancer Science & Therapy 2013, 5: 264-270.
  9. Unguru Y.*, Joffe S., Fernandez C.V., Yu A.L. Ethical issues for control-arm patients after revelation of benefits of experimental therapy: a framework modeled in neuroblastoma. J Clin Oncol 2013, 31(5): 641-646.
  10. Williams R.T., Yu A.L., Diccianni M.B., Theodorakis E.A., Batova A.* Renal cancer-selective Englerin A induces multiple mechanisms of cell death and autophagy. J Exp Clin Cancer Res 2013, 32(1): 57.
  11. Barnhill L.M., Williams R.T., Cohen O., Kim Y., Batova A., Mielke J.A., Messer K., Pu M., Bao L., Yu A.L.*, Diccianni M.B.* High Expression of CAI2, a 9p21-Embedded Long Noncoding RNA, Contributes to Advanced-Stage Neuroblastoma. Cancer Res 2014, 74(14): 3753-3763.
  12. Fu C.H., Lin R.J., Yu J., Chang W.W., Liao G.S., Chang W.Y., Tseng L.M., Tsai Y.F., Yu J.C., Yu A.L.* A Novel Oncogenic Role of Inositol Phosphatase SHIP2 in ER-Negative Breast Cancer Stem Cells: Involvement of JNK/Vimentin Activation. Stem Cells 2014, 32(8): 2048-2060.
  13. Huang J.R., Tsai Y.C., Chang Y.J., Wu J.C., Hung J.T., Lin K.H., Wong C.H., Yu A.L.* alpha-Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2/3. J Immunol 2014, 192(4): 1972-1981.
  14. Hung J.T., Tsai Y.C., Lin W.D., Jan J.T., Lin K.H., Huang J.R., Cheng J.Y., Chen M.W., Wong C.H.*, Yu A.L.* Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus. Antiviral Res 2014, 107: 110-118.
  15. Hung J.T., Sawant R.C., Chen J.C., Yen Y.F., Chen W.S., Yu A.L.*, Luo S.Y.* Design and synthesis of galactose-6-OH-modified α-galactosyl ceramide analogues with Th2-biased immune responses. RSC Advances 2014, 4:47341-56.
  16. Kelner M.J., Diccianni M.B., Yu A.L., Rutherford M.R., Estes L.A., Morgenstern R. Absence of MGST1 mRNA and protein expression in human neuroblastoma cell lines and primary tissue. Free Radic Biol Med 2014, 69: 167-171.
  17. Lin J., Chang Y.J., Yang W.B., Yu A.L.*, Wong C.H.* The Multifaceted Effects of Polysaccharides Isolated from Dendrobium huoshanense on Immune Functions with the Induction of Interleukin-1 Receptor Antagonist (IL-1ra) in Monocytes. PLoS One 2014, 9(4): e94040.
  18. Lin J.J., Huang C.S., Yu J., Liao G.S., Lien H.C., Hung J.T., Lin R.J., Chou F.P., Yeh K.T., Yu A.L.* Malignant phyllodes tumors display mesenchymal stem cell features and aldehyde dehydrogenase/disialoganglioside identify their tumor stem cells. Breast Cancer Research 2014, 16(2): R29.
  19. Sonawane P., Cho H.E., Tagde A., Verlekar D., Yu A.L., Reynolds C.P., Kang M.H. Metabolic characteristics of 13-cis retinoic acid (isotretinoin) and anti-tumor activity of the 13-cis retinoic acid metabolite 4-oxo-13-cis retinoic acid in neuroblastoma. Br J Pharmacol 2014, 171(23): 5330-44.
  20. Terme M., Dorvillius M., Cochonneau D., Chaumette T., Xiao W., Diccianni M.B., Barbet J., Yu A.L., Paris F., Sorkin L.S., Birkle S.* Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia. PLoS One 2014, 9(2): e87210.
  21. Williams R.T., Barnhill L.M., Kuo H.H., Lin W.D., Batova A., Yu A.L., Diccianni M.B.* Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth. PLoS One 2014, 9(2): e88219.
  22. Chang C.H., Fan T.C., Yu J.C., Liao G.S., Lin Y.C., Shih A.C., Li W.H., and Yu A.L.* The prognostic significance of RUNX2 and miR-10a/10b and their inter-relationship in breast cancer. Journal of Translational Medicine 2014, 12: 257.
  23. Cheng J.Y., Wang S.H., Lin J., Tsai Y.C., Yu J., Wu J.C., Hung J.T., Lin J.J., Wu Y.Y., Yeh K.T., and Yu A.L.* Globo-H ceramide shed from cancer cells triggers translin-associated factor X-dependent angiogenesis. Cancer Research 2014, 74: 6856-66.
  24. Lin H.H, Lee H.W, Lin R.J., Huang C.W., Liao Y.C., Chen Y.T., Fang J.M., Lee T.C., Yu A.L.*, and Chang H.C.* Tracking and finding slow-proliferating/quiescent cancer stem cells with fluorescent nanodiamonds. Small 2015, 11: 4394-402.
  25. Wang S.H., Lee A.C., Chen I.J., Chang N.C., Wu H.C., Yu H.M., Chang Y.J., Lee T.W., Yu J.C., Yu A.L.*, and Yu J.* Structure-based optimization of GRP78-binding peptides that enhances efficacy in cancer imaging and therapy. Biomaterials 2016, 94:31-44.
  26. Tan K.P., Ho M.Y., Cho H.C., Yu J., Hung J.T., Yu A.L.* Fucosylation of LAMP-1 and LAMP-2 by FUT1 correlates with lysosomal positioning and autophagic flux of breast cancer cells. Cell Death & Disease, 2016, 7(8): e2347.
  27. Ho M.Y., Yu A.L., Yu J.* Glycosphingolipid dynamics in human embryonic stem cell and cancer: their characterization and biomedical implications. Glycoconjugate Journal 2016, DOI: 10.1007/s10719-016-9715-x.
  28. Yu A.L., Hung J.T., Ho M.Y., Yu J*. Alterations of glycosphingolipids in embryonic stem cell differentiation and development of glycan-targeting cancer immunotherapy. Stem Cell and Development 2016, 25(20): 1532-1548.
  29. Hung J.T., Yeh C.H., Yang S.A., Lin C.Y., Tsai H.J., Shelke G.B., Reddy D.M., Yu A.L.*, Luo S.Y.* Design, synthesis and biological evaluation of ganglioside Hp-s1 analogues varying at glucosyl moiety. ACS Chemical Neuroscience 2016, 7(8): 1107-11.
  30. Hung J.T., Sawant R.C., Wang S.H., Huang J.R., Huang C.L., Yang S.A., Shelke G.B., Yu J., Yu A.L., Luo S.Y.* Structure-based design of NH-modified α-galactosyl ceramide (KRN7000) analogues and their biological activities. ChemistrySelect 2016, 1:4564-69.
  31. Wu T.N., Lin K.H., Wu Y.T., Huang J.R., Hung J.T., Wu J.C., Chen C.Y., Chu K.C., Lin N.H., Yu A.L.*, Wong C.H.* Phenyl glycolipids with different glycosyl groups exhibit marked differences in murine and human iNKT cell activation. ACS Chemical Biology 2016, 11(12): 3431-41.
  32. Hung J.T., Yu A.L. Targeting Glycans for Immunotherapy of Human Cancers. In Glycosignals in Cancer: Mechanisms of Malignant Phenotypes, Chapter 11, pp 197-219. Edited by Koichi F. and Minoru F. Springer Japan, 2016.
  33. Nai Y.S., Chen T.H., Huang Y.F., Midha M.K., Shiau H.C., Shen C.Y., Chen C.J., Yu A.L., Chiu K.P.* T oligo-primed polymerase chain reaction (TOP-PCR): a robust method for the amplification of minute DNA fragments in body fluids. Scientific Reports 2017, 7:40767.
  34. Hung J.T., Huang J.R., Yu A.L.* Tailored design of NKT-stimulatory glycolipids for polarization of immune responses. J Biomedical Science 2017, 24(1):22.
  35. Mody R., Naranjo A., Van Ryn C., Yu A.L., London W.B., Shulkin B.L., Parisi M.T., Servaes S., Diccianni M.B., Sondel P.M., Maris J.M., Park J.R., Bagatell R.* Irinotecan-temozolomide with temsirolimus or Dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomized, phase 2 trial. The Lancet Oncology 2017, DOI:
  36. Batova A.*, Altomare D., Creek K.E., Naviaux R.K., Wang L., Li K., Green E., Williams R., Naviaux J.C., Diccianni M., Yu A.L. Englerin A induces an acute inflammatory response and reveals lipid metabolism and ER stress as targetable vulnerabilities in renal cell carcinoma. Plos One 2017, 12(3): e0172632.
  37. Krbe A.K., Wang W., Carmichael L., Kim K., Mendonca E.A., Song Y., Hess D., Reville P.K., London W.B., Naranjo A., Hank J.A., Diccianni M.B., Reisfeld R.A., Gillies S.D., Matthay K.K., Cohn S.L., Hogarty M.D., Maris J.M., Park J.R., Ozkaynak F., Gilman A., Yu A.L.*, Sondel P.M.* Neuroblastoma patients’ KIR and KIR-ligand genotypes influence clinical outcome for dinutuximab-based immunotherapy: a report from the Children’s Oncology Group. Clinical Cancer Research 2017, Published OnlineFirst on October 2, 2017; DOI: 10.1158/1078-0432.CCR-17-1767
  38. Kuo H.H., Lin R.J., Hung J.T., Hsieh C.B., Hung T.H., Lo F.Y., Ho M.Y., Yeh C.T., Huang Y.L., Yu J.*, Yu A.L.* High expression FUT1 and B3GALT5 is an independent predictor of postoperative recurrence and survival in hepatocellular carcinoma. Scientific Reports 2017, 7:10750.
  39. Krbe A.K., Wang W., Reville P.K., Carmichael L., Kim K.M., Mendonca E.A., Song Y., Hank J.A., London W.B., Naranjo A., Hong F., Hogarty M.D., Maris J.M., Park J.R., Ozkaynak M.F., Miller J.S., Gilman A.L., Kahl B., Yu A.L., Sondel P.M.* HLA-Bw4-I-80 isoform differentially influences clinical outcome as compared to HLA-Bw4-T-80 and HLA-A-Bw4 isoforms in rituximab or dinutuximab-based cancer immunotherapy. Frontiers in Immunology 2017, 8:1-9.
  40. Huang Y.F., Chen Y.J., Fan T.C., Chang N.C., Chen Y.J., Midha M.K., Chen T.H., Yang H.H., Wang Y.T., Yu A.L., Chiu K.P.* Analysis of microbial sequences in plasma cell-free DNA for early-onset breast cancer patients and healthy females. BMC Genetics, 2017, in press.
  41. Liao C.H., Chang W.W., Yang B.C., Wang Y.H., Liu W.L., Yu A.L., Yu J.* Leucine-rich Repeat Neuronal Protein 1 Regulates Differentiation of Human Embryonic Stem Cells by Posttranslational Modifications of Pluripotency Factors. Stem Cells 2017, in revision.
  42. Tsai C.T., Kuo M.W., Lin J.L., Yu A.L., Yu J.* Deficiency of a Novel Gene, Yulink, Predisposes to Heart Failure and Ventricular Arrhythmia. FASEB J. 2017, in revision.
  43. Cho H.C., Lai L.C., Huang Y.L., Wang S.H., Cho I.M., Kuo M.W., Cheng P.Y., Ho M.Y., Liu Y.H., Lin R.J., Yu A.L., Yu J.* Puf-A, a novel 5.8S ribonucleoprotein of 90S pre-ribosome, links ribosome biogenesis to cancer progression. Nature Cell Biology 2017, submitted.